Back

High bleeding risk mainly predicts non-access site bleeding events in the first month after percutaneous coronary intervention

26 August 2023 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Renal failure and bleeding in PCI patients Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Ms Eva Christine Ida Woelders

Radboud University Medical Centre, Nijmegen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Comparison of percutaneous coronary intervention versus medication in dialysis patients with coronary artery disease
Doctor E. Xie (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events.
Doctor S. Ikebe (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
Parsimonious versus extensive score: can we simplify bleeding risk stratification after percutaneous coronary intervention without losing specificity?
Ms E. Woelders (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Platelet reactivity and activated clotting time predict haemorrhagic site complications in patients with chronic coronary syndromes undergoing percutaneous coronary intervention
Doctor B. Ramotowski (Warsaw, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Renal failure and bleeding in PCI patients

The Event

Event poster

ESC Congress 2023

26 August 2023 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Parsimonious versus extensive score: can we simplify bleeding risk stratification after percutaneous coronary intervention without losing specificity?
thumbnail
Congress Presentation
Prospective validation of the ARC HBR trade off model in the all comer PIONEER IV trial
thumbnail
Congress Presentation
Timing of bleeding and ischemic events after PCI in high and very high bleeding risk patients treated with 1-month DAPT: a patient-level pooled analysis of clinical trials

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources